-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A study from the University of Houston School of Pharmacy, published in the Journal of the American Academy of Geriatrics, assessed the risk of overactive bladder (OAB), a cholinesterase inhibitor (ChEI) treatment for dementia and Alzheimer's disease side effects of medicines
Dementia is a group of symptoms associated with a decline in memory, reasoning or other thinking skills
"The study found that the risk of overactive bladder varies with individual ChEIs," reports the Rajender R.
Using Medicare data, the study looked at 524,975 Alzheimer's patients (65 years and older) using ChEIs (80.
While several studies have been conducted to assess the effects of all ChEIs and anti-chlorpyrifos use, few studies have addressed the effects of individual ChEIs on OAB risk
This research opens a new door
"The findings suggest a need to understand and manage drug-related morbidity in Alzheimer's patients," Aparasu said